Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
A Study of CPI-0209 in Patients with Advanced Solid Tumors and Lymphomas
Phase 1/2
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Phase 2
The purpose of the study is to assess whether an investigational drug, called XmAb20717, has any effects on certain types of cancers and if it is safe and well tolerated.
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
The purpose of this study is to determine if individuals diagnosed with palmoplantar pustulosis (PPP) would benefit from treatment with Deucravacitinib.
Comparative Effectiveness of Spironolactone Versus Doxycycline for Acne
Phase 4
Are you interested in contributing to skin research? Join our Acne Research Study, where we aim to compare the effectiveness of Spironolactone and Doxycycline Hyclate in the treatment of moderate to severe acne in women. Both medications are common treatments for acne, but it is not known how well they compare to one another.
HPTN 102: LEN in Women (HIV Prevention Medication)
Phase 2
This is a Phase 2, open-label, multicenter, randomized study to evaluate the
PK, safety, and acceptability of LEN subcutaneous (SC) injection compared with oral F/TDF in cisgender women who would benefit from PrEP. This study has 2 parts. Randomized Phase: ppts will be randomized in a 1:1 ratio to receive 52 wks of LEN or F/TDF, followed by up to 78 wks of F/TDF for both study drug groups in the PK Tail Phase. Participants in the LEN group will transition to F/TDF for the PK Tail Phase.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
